About two-thirds of new drugs fail to meet sales expectations in the first year on the market and many continue to underperform three years post-launch, costing the industry hundreds of millions of dollars in lost revenue.
Before an initial commercial launch, it’s critical for emerging pharma and biotech companies to implement a data-driven well-defined launch strategy years in advance in order to reach their goals.
Read the whitepaper to learn from the experiences of 100+ launches and get started on your path to launch success. You will learn: